Skip to main content
Terug
GYRE logo

Gyre Therapeutics, Inc.

Datakwaliteit: 100%
GYRE
NASDAQ Healthcare Biotechnology
€ 6,94
▼ € 0,10 (-1,42%)
Marktkapitalisatie: 630,78M
Dagbereik
€ 6,91 € 7,24
52-Weeksbereik
€ 6,11 € 11,78
Volume
115.642
50D / 200D Gem.
€ 7,92 / € 7,75
Vorige Slotkoers
€ 7,04

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E 125,5 0,3
P/B 6,0 2,9
ROE % 5,9 3,7
Net Margin % 4,3 3,8
Rev Growth 5Y % 99,7 10,0
D/E 0,0 0,2

Koersdoel Analisten

Hold
€ 16,00 +130.5%
Forward WPA
-€ 0,32
Omzet Sch.
140 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 0,25
€ 0,21 – € 0,31
310 M 1
FY2029 € 0,11
€ 0,09 – € 0,14
270 M 1
FY2028 € 1,71
€ 1,42 – € 2,12
440 M 1

Belangrijkste Punten

Revenue grew 99,65% annually over 5 years — strong growth
Earnings declined -58,40% over the past year
Debt/Equity of 0,01 — conservative balance sheet
Negative free cash flow of -180.000,0
P/E of 125,48 — premium valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 89,41%

Groei

Revenue Growth (5Y)
99,65%
Revenue (1Y)10,24%
Earnings (1Y)-58,40%
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
5,94%
ROIC8,05%
Net Margin4,31%
Op. Margin9,85%

Veiligheid

Debt / Equity
0,01
Current Ratio5,60
Interest Coverage0,00

Waardering

P/E Ratio
125,48
P/B Ratio5,95
EV/EBITDA51,77
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 10,24% Revenue Growth (3Y) 1,37%
Earnings Growth (1Y) -58,40% Earnings Growth (3Y) N/A
Revenue Growth (5Y) 99,65% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 116,59M Net Income (TTM) 5,03M
ROE 5,94% ROA 3,03%
Gross Margin 95,35% Operating Margin 9,85%
Net Margin 4,31% Free Cash Flow (TTM) -180.000,0
ROIC 8,05% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,01 Current Ratio 5,60
Interest Coverage 0,00 Dividend Yield 0,00%
Valuation
P/E Ratio 125,48 P/B Ratio 5,95
P/S Ratio 5,41 PEG Ratio -2,10
EV/EBITDA 51,77 Dividend Yield 0,00%
Market Cap 630,78M Enterprise Value 594,65M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 116,59M 105,76M 113,45M 102,29M 7,34M
Net Income 5,03M 12,09M -92,93M 2,30M -87,93M
EPS (Diluted) 0,02 0,05 -1,41 0,03 -2,87
Gross Profit 111,17M 101,87M 108,81M 97,50M -332.000,0
Operating Income 11,49M 16,16M -67,23M 9,20M -83,73M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 166,13M 125,41M 116,54M 84,75M 55,66M
Total Liabilities 23,85M 27,00M 102,59M 12,54M 14,57M
Shareholders' Equity 106,03M 63,32M -15,83M 42,52M 41,09M
Total Debt 939.000,0 1,60M 409.000,0 613.000,0 2,39M
Cash & Equivalents 37,07M 11,81M 33,51M 25,18M 44,35M
Current Assets 102,37M 64,79M 57,22M 49,65M 51,48M
Current Liabilities 18,29M 19,52M 20,05M 12,24M 14,17M